<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727270</url>
  </required_header>
  <id_info>
    <org_study_id>15183</org_study_id>
    <secondary_id>3794</secondary_id>
    <secondary_id>5338</secondary_id>
    <secondary_id>4546</secondary_id>
    <secondary_id>7186</secondary_id>
    <nct_id>NCT02727270</nct_id>
  </id_info>
  <brief_title>Measuring Cortisol Levels in Persons With Parkinson's (PD)</brief_title>
  <acronym>CORT-PD</acronym>
  <official_title>Measuring Cortisol Levels in Persons With Parkinson's (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Portland VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Clinical and Translational Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntingtons Disease Society of America (HDSA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the cortisol awakening response with persons with&#xD;
      Parkinsons Disease (PD), Huntingtons Disease (HD), and controls. These data are desired so&#xD;
      experience can be gained with measuring stress levels subjectively and objectively in persons&#xD;
      with PD, HD, and controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Telephone consent will be obtained.&#xD;
&#xD;
      Participants will collect saliva at twelve time points - four times a day for three days.&#xD;
&#xD;
      Visits will be conducted virtually (over the internet).&#xD;
&#xD;
      The virtual visit is to assess Parkinson's or Huntington's disease status, stress, mood, and&#xD;
      quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Awakening Salivary Cortisol level (ug/dL) Response</measure>
    <time_frame>Collected upon awakening and 30 minutes after awakening</time_frame>
    <description>Salivary Cortisol level (ug/dL) Response is the change in cortisol between awakening and 30 minutes after awakening.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's - High Stress</arm_group_label>
    <description>Parkinson's disease patients with self-reported high strain/stress.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's - Low Stress</arm_group_label>
    <description>Parkinson's disease patients with self-reported low strain/stress.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls - High Stress</arm_group_label>
    <description>Healthy controls (no neurological disease) with self-reported high strain/stress.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls - Low Stress</arm_group_label>
    <description>Healthy controls (no neurological disease) with self-reported low strain/stress.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Huntington's - High Stress</arm_group_label>
    <description>Huntington's disease patients with self-reported high strain/stress.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Huntington's - Low Stress</arm_group_label>
    <description>Huntington's disease patients with self-reported low strain/stress.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention - Observational Study</intervention_name>
    <description>No Intervention - Observational Study</description>
    <arm_group_label>Controls - High Stress</arm_group_label>
    <arm_group_label>Controls - Low Stress</arm_group_label>
    <arm_group_label>Huntington's - High Stress</arm_group_label>
    <arm_group_label>Huntington's - Low Stress</arm_group_label>
    <arm_group_label>Parkinson's - High Stress</arm_group_label>
    <arm_group_label>Parkinson's - Low Stress</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators plan to enroll seven groups: (1) person with PD and moderate levels of&#xD;
        self-reported stress, (2) persons with PD and low levels of self-reported stress, (3)&#xD;
        controls and moderate levels of self-reported stress, (4) controls and low levels of&#xD;
        self-reported stress, (5) persons with HD and moderate/high levels of self-reported stress,&#xD;
        and (6) persons with HD a low levels of self-reported stress, and (7) those that completed&#xD;
        the study prior to COVID-19 restrictions in March of 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group (1) Inclusion:&#xD;
&#xD;
          -  PD as confirmed by NINDS criteria&#xD;
&#xD;
          -  PD confirmed by a movement disorders specialist&#xD;
&#xD;
          -  a Perceived Stress Scale (PSS) score higher than or equal to 13.&#xD;
&#xD;
        Group (2) Inclusion:&#xD;
&#xD;
          -  PD as confirmed by NINDS criteria&#xD;
&#xD;
          -  PD confirmed by a movement disorders specialist&#xD;
&#xD;
          -  PSS score lower than 13.&#xD;
&#xD;
        Group (3) Inclusion:&#xD;
&#xD;
          -  No significant neurological disorder&#xD;
&#xD;
          -  PSS score of greater than or equal to 13.&#xD;
&#xD;
        Group (4) Inclusion:&#xD;
&#xD;
          -  No significant neurological disorder&#xD;
&#xD;
          -  PSS score of less than 13.&#xD;
&#xD;
        Group (5) Inclusion:&#xD;
&#xD;
          -  HD diagnosis&#xD;
&#xD;
          -  HD confirmed by a movement disorders specialist&#xD;
&#xD;
          -  a Perceived Stress Scale (PSS) score higher than or equal to 13.&#xD;
&#xD;
        Group (6) Inclusion:&#xD;
&#xD;
          -  HD diagnosis&#xD;
&#xD;
          -  HD confirmed by a movement disorders specialist&#xD;
&#xD;
          -  PSS score lower than 13&#xD;
&#xD;
        Group (7) Inclusion:&#xD;
&#xD;
          -  Completion of the study prior to COVID-19 Restrictions in March of 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The use of medications known to effect cortisol levels (estrogen, synthetic&#xD;
             glucocorticoids, androgens, phenytoin, spironolactone, prednisone, prednisolone, and&#xD;
             hydrocortisone).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amie L Hiller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brenna M Lobb, MS, MPH</last_name>
    <phone>503.220.8262</phone>
    <phone_ext>51871</phone_ext>
    <email>lobbb@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan M O'Connor, RN</last_name>
    <phone>503.220.8262</phone>
    <phone_ext>51091</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Universtiy</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenna Lobb, MS MPH</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>51871</phone_ext>
      <email>lobbb@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenna Lobb, MS MPH</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>51871</phone_ext>
      <email>lobbb@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, Volterrani D, Bonuccelli U. Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction. Eur J Neurol. 2013 Mar;20(3):480-485. doi: 10.1111/j.1468-1331.2012.03878.x. Epub 2012 Oct 18.</citation>
    <PMID>23078376</PMID>
  </reference>
  <reference>
    <citation>Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997 May-Jun;18(3):285-9.</citation>
    <PMID>9263193</PMID>
  </reference>
  <reference>
    <citation>Marsden CD, Owen DA. Mechanisms underlying emotional variation in parkinsonian tremor. Neurology. 1967 Jul;17(7):711-5.</citation>
    <PMID>6067490</PMID>
  </reference>
  <reference>
    <citation>Matousek RH, Dobkin PL, Pruessner J. Cortisol as a marker for improvement in mindfulness-based stress reduction. Complement Ther Clin Pract. 2010 Feb;16(1):13-9. doi: 10.1016/j.ctcp.2009.06.004. Epub 2009 Jul 4. Review.</citation>
    <PMID>20129404</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Amie Hiller, MD</investigator_full_name>
    <investigator_title>Neurologist</investigator_title>
  </responsible_party>
  <keyword>Movement disorders</keyword>
  <keyword>Metabolic Stress</keyword>
  <keyword>Basal Ganglia Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data be available (including data dictionaries). Individual participant data that underlie the results reported the resultant article, after deidentification (text, tables, figures, and appendices). In addition to data, the study protocol and the informed consent form (ICF) will be provided. Data will be available beginning 6 months and ending 2 years following article publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>6 months - 2 years following article publication</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with Investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose. Data will be released to achieve aims in the approved proposal or for individual participant data meta-analysis.</ipd_access_criteria>
    <ipd_url>https://www.parkinsons.va.gov/northwest/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

